Clinical impact of ki-67 labeling index in non-small cell lung cancer

Lung Cancer

Volumn 79, Issue 1, 2013, Pages 1-7

  Jakobsen, Jan Nyrop ^a   Sørensen, Jens Benn ^a  

^a Rigshospitalet   (Denmark)

Author keywords

Ki 67; Labeling index; MIB 1; NSCLC; Predictive marker; Proliferation marker

Indexed keywords

BIOLOGICAL MARKER; KI 67 ANTIGEN;

CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CONSENSUS; HISTOPATHOLOGY; HUMAN; LABELING INDEX; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROGNOSIS; REVIEW; STANDARDIZATION;

ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; CELL PROLIFERATION; HUMANS; KI-67 ANTIGEN; LUNG NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84871073608     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2012.10.008     Document Type: Review

References (76)

1. United States Cancer Statistics: 2002-2004 Incidence and Mortality Web-based Report Version. Atlanta (GA): Department of Health and Human Services, Centers for Disease Control and Prevention, and National Cancer Institute. Journal of the National Cancer Institute 2007.
2. Shepherd F.A., Crowley J., Van Houtte P., Postmus P.E., Carney D., Chansky K., et al. The International Association for the Study of Lung Cancer lung cancer staging project: proposals regarding the clinical staging of small cell lung cancer in the forthcoming (seventh) edition of the tumor, node, metastasis classification for lung cancer. J Thorac Oncol 2007, 2(12):1067-1077.
3. Stinchcombe T.E., Socinski M.A. Treatment paradigms for advanced stage non-small cell lung cancer in the era of multiple lines of therapy. J Thorac Oncol 2009, 4(2):243-250.
4. Goffin J., Lacchetti C., Ellis P.M., Ung Y.C., Evans W.K., Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-Based Care, et al. First-line systemic chemotherapy in the treatment of advanced non-small cell lung cancer: a systematic review. J Thorac Oncol 2010, 5(2):260-274.
5. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Krook J., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002, 346(2):92-98.
6. Scagliotti G.V., Parikh P., von Pawel J., Biesma B., Vansteenkiste J., Manegold C., et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008, 26(21):3543-3551.
7. Gridelli C., De Marinis F., Di Maio M., Cortinovis D., Cappuzzo F., Mok T., et al. Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: implications for clinical practice and open issues. Lung Cancer 2011, 72(1):3-8.
8. Shaw A.T., Yeap B.Y., Solomon B.J., Riely G.J., Gainor J., Engelman J.A., et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol 2011, 12(11):1004-1012.
9. Gerdes J., Schwab U., Lemke H., Stein H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 1983, 31(1):13-20.
10. Bullwinkel J., Baron-Lühr B., Lüdemann A., Wohlenberg C., Gerdes J., Scholzen T., et al. Ki-67 protein is associated with ribosomal RNA transcription in quiescent and proliferating cells. J Cell Physiol 2006, 206(3):624-635.
11. Rahmanzadeh R., Hüttmann G., Gerdes J., Scholzen T. Chromophore-assisted light inactivation of pKi-67 leads to inhibition of ribosomal RNA synthesis. Cell Prolif 2007, 40(3):422-430.
12. Gerdes J., Lemke H., Baisch H., Wacker H.H., Schwab U., Stein H., et al. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 1984, 133(4):1710-1715.
13. Alexandrakis M.G., Passam F.H., Kyriakou D.S., Dambaki K., Niniraki M., Stathopoulos E., et al. Ki-67 proliferation index: correlation with prognostic parameters and outcome in multiple myeloma. Am J Clin Oncol 2004, 27(1):8-13.
14. Li R., Heydon K., Hammond M.E., Grignon D.J., Roach M., Wolkov H.B., et al. Ki-67 staining index predicts distant metastasis and survival in locally advanced prostate cancer treated with radiotherapy: an analysis of patients in radiation therapy oncology group protocol 86-10. Clin Cancer Res 2004, 10(12 Pt 1):4118-4124.
15. Scholzen T., Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol 2000, 182(3):311-322.
16. Urruticoechea A., Smith I.E., Dowsett M. Proliferation marker Ki-67 in early breast cancer. J Clin Oncol 2005, 23(28):7212-7220.
17. Stuart-Harris R., Caldas C., Pinder S.E., Pharoah P. Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients. Breast 2008, 17(4):323-334.
18. Cummings T.J., Provenzale J.M., Hunter S.B., Friedman A.H., Klintworth G.K., Bigner S.H., et al. Gliomas of the optic nerve: histological, immunohistochemical (MIB-1 and p53), and MRI analysis. Acta Neuropathol 2000, 99(5):563-570.
19. Zlotta A.R., Schulman C.C. Biological markers in superficial bladder tumors and their prognostic significance. Urol Clin North Am 2000, 27(1):179-189. [xi].
20. Indinnimeo M., Cicchini C., Stazi A., Limiti M.R., Ghini C., Mingazzini P., et al. Immunohistochemical assessment of Ki-67 as prognostic cellular proliferation marker in anal canal carcinoma. J Exp Clin Cancer Res 2000, 19(4):471-475.
21. Jamali M., Chetty R. Predicting prognosis in gastroentero-pancreatic neuroendocrine tumors: an overview and the value of Ki-67 immunostaining. Endocr Pathol 2008, 19(4):282-288.
22. Klimstra D.S., Modlin I.R., Coppola D., Lloyd R.V., Suster S. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas 2010, 39(6):707-712.
23. Beasley M.B., Thunnissen F.B., Brambilla E., Hasleton P., Steele R., Hammar S.P., et al. Pulmonary atypical carcinoid: predictors of survival in 106 cases. Hum Pathol 2000, 31(10):1255-1265.
24. Travis W., Brambilla E., Muller-Hermelink H., Harris C. World health classification of tumours: pathology and genetics of tumours of the lung, pleura, thymus, and heart 2004, IARC Press, Lyon.
25. Tubiana M., Courdi A. Cell proliferation kinetics in human solid tumors: relation to probability of metastatic dissemination and long-term survival. Radiother Oncol 1989, 15(1):1-18.
26. Nishimura R., Osako T., Okumura Y., Hayashi M., Arima N. Clinical significance of Ki-67 in neoadjuvant chemotherapy for primary breast cancer as a predictor for chemosensitivity and for prognosis. Breast Cancer 2010, 17(4):269-275.
27. Pippen J., Paul D., Stokoe C., Blum J., Krekow L., Holmes F., et al. Exploratory Ki-67 analyses suggest benefit of capecitabine in high-risk early breast cancer. J Clin Oncol 2011, 29. [suppl; abstr 500].
28. Hugh J., Hanson J., Cheang M.C.U., Nielsen T.O., Perou C.M., Dumontet C., et al. Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol 2009, 27(8):1168-1176.
29. Penault-Llorca F., André F., Sagan C., Lacroix-Triki M., Denoux Y., Verriele V., et al. Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer. J Clin Oncol 2009, 27(17):2809-2815.
30. Viale G., Regan M.M., Mastropasqua M.G., Maffini F., Maiorano E., Colleoni M., et al. Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. J Natl Cancer Inst 2008, 100(3):207-212.
31. Haga Y., Hiroshima K., Iyoda A., Shibuya K., Shimamura F., Iizasa T., et al. Ki-67 expression and prognosis for smokers with resected stage I non-small cell lung cancer. Ann Thorac Surg 2003, 75(6):1727-1732. [discussion 1732].
32. Tsubochi H., Sato N., Hiyama M., Kaimori M., Endo S., Sohara Y., et al. Combined analysis of cyclooxygenase-2 expression with p53 and Ki-67 in nonsmall cell lung cancer. Ann Thorac Surg 2006, 82(4):1198-1204.
33. Cagini L., Monacelli M., Giustozzi G., Moggi L., Bellezza G., Sidoni A., et al. Biological prognostic factors for early stage completely resected non-small cell lung cancer. J Surg Oncol 2000, 74(1):53-60.
34. Minami K.I., Saito Y., Imamura H., Okamura A. Prognostic significance of p53, Ki-67, VEGF and Glut-1 in resected stage I adenocarcinoma of the lung. Lung Cancer 2002, 38(1):51-57.
35. Shiba M., Kohno H., Kakizawa K., Iizasa T., Otsuji M., Saitoh Y., et al. Ki-67 immunostaining and other prognostic factors including tobacco smoking in patients with resected nonsmall cell lung carcinoma. Cancer 2000, 89(7):1457-1465.
36. Demarchi L.M., Reis M.M., Palomino S.A., Farhat C., Takagaki T.Y., Beyruti R., et al. Prognostic values of stromal proportion and PCNA, Ki-67, and p53 proteins in patients with resected adenocarcinoma of the lung. Mod Pathol 2000, 13(5):511-520.
37. Huang C., Liu D., Masuya D., Nakashima T., Kameyama K., Ishikawa S., et al. Clinical application of biological markers for treatments of resectable non-small-cell lung cancers. Br J Cancer 2005, 92(7):1231-1239.
38. Imai H., Kaira K., Oriuchi N., Yanagitani N., Sunaga N., Ishizuka T., et al. l-type amino acid transporter 1 expression is a prognostic marker in patients with surgically resected stage I non-small cell lung cancer. Histopathology 2009, 54(7):804-813.
39. Kaira K., Oriuchi N., Imai H., Shimizu K., Yanagitani N., Sunaga N., et al. Prognostic significance of l-type amino acid transporter 1 expression in resectable stage I-III nonsmall cell lung cancer. Br J Cancer 2008, 98(4):742-748.
40. Yang J., Ramnath N., Moysich K.B., Asch H.L., Swede H., Alrawi S.J., et al. Prognostic significance of MCM2, Ki-67 and gelsolin in non-small cell lung cancer. BMC Cancer 2006, 6:203.
41. Takahashi S., Kamata Y., Tamo W., Koyanagi M., Hatanaka R., Yamada Y., et al. Relationship between postoperative recurrence and expression of cyclin E, p27, and Ki-67 in non-small cell lung cancer without lymph node metastases. Int J Clin Oncol 2002, 7(6):349-355.
42. Yoo J., Jung J.H., Lee M.A., Seo K.J., Shim B.Y., Kim S.H., et al. Immunohistochemical analysis of non-small cell lung cancer: correlation with clinical parameters and prognosis. J Korean Med Sci 2007, 22(2):318-325.
43. Hommura F., Dosaka-Akita H., Mishina T., Nishi M., Kojima T., Hiroumi H., et al. Prognostic significance of p27KIP1 protein and ki-67 growth fraction in non-small cell lung cancers. Clin Cancer Res 2000, 6(10):4073-4081.
44. 18F-FDG PET activity with expressions of survivin, Ki67, and CD34 in non-small-cell lung cancer. Nucl Med Commun 2009, 30(11):831-837.
45. Pelosi G., Fraggetta F., Pasini F., Maisonneuve P., Sonzogni A., Iannucci A., et al. Immunoreactivity for thyroid transcription factor-1 in stage I non-small cell carcinomas of the lung. Am J Surg Pathol 2001, 25(3):363-372.
46. Yamashita S.I., Moroga T., Tokuishi K., Miyawaki M., Chujo M., Yamamoto S., et al. Ki-67 labeling index is associated with recurrence after segmentectomy under video-assisted thoracoscopic surgery in stage I non-small cell lung cancer. Ann Thorac Cardiovasc Surg 2011, 17(4):341-346.
47. Woo T., Okudela K., Yazawa T., Wada N., Ogawa N., Ishiwa N., et al. Prognostic value of KRAS mutations and Ki-67 expression in stage I lung adenocarcinomas. Lung Cancer 2009, 65(3):355-362.
48. Nguyen X.C., Lee W.W., Chung J.H., Park S.Y., Sung S.W., Kim Y.K., et al. FDG uptake, glucose transporter type 1, and Ki-67 expressions in non-small-cell lung cancer: correlations and prognostic values. Eur J Radiol 2007, 62(2):214-219.
49. Rigau V., Molina T.J., Chaffaud C., Huchon G., Audouin J., Chevret S., et al. Blood vessel invasion in resected non small cell lung carcinomas is predictive of metastatic occurrence. Lung Cancer 2002, 38(2):169-176.
50. Puglisi F., Minisini A.M., Aprile G., Barbone F., Cataldi P., Artico D., et al. Balance between cell division and cell death as predictor of survival in patients with non-small-cell lung cancer. Oncology 2002, 63(1):76-83.
51. Maddau C., Confortini M., Bisanzi S., Janni A., Montinaro F., Paci E., et al. Prognostic significance of p53 and Ki-67 antigen expression in surgically treated non-small cell lung cancer: immunocytochemical detection with imprint cytology. Am J Clin Pathol 2006, 125(3):425-431.
52. Filipits M., Pirker R., Dunant A., Lantuejoul S., Schmid K., Huynh A., et al. Cell cycle regulators and outcome of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer: the International Adjuvant Lung Cancer Trial Biologic Program. J Clin Oncol 2007, 25(19):2735-2740.
53. Inoue M., Takakuwa T., Minami M., Shiono H., Utsumi T., Kadota Y., et al. Clinicopathologic factors influencing postoperative prognosis in patients with small-sized adenocarcinoma of the lung. J Thorac Cardiovasc Surg 2008, 135(4):830-836.
54. Carbognani P., Tincani G., Crafa P., Sansebastiano G., Pazzini L., Zoni R., et al. Biological markers in non-small cell lung cancer. Retrospective study of 10 year follow-up after surgery. J Cardiovasc Surg (Torino) 2002, 43(4):545-548.
55. Nguyen V.N., Mirejovský P., Mirejovský T., Melínová L., Mandys V. Expression of cyclin D1, Ki-67 and PCNA in non-small cell lung cancer: prognostic significance and comparison with p53 and bcl-2. Acta Histochem 2000, 102(3):323-338.
56. Ramnath N., Hernandez F.J., Tan D.F., Huberman J.A., Natarajan N., Beck A.F., et al. MCM2 is an independent predictor of survival in patients with non-small-cell lung cancer. J Clin Oncol 2001, 19(22):4259-4266.
57. David O., Jett J., LeBeau H., Dy G., Hughes J., Friedman M., et al. Phospho-Akt overexpression in non-small cell lung cancer confers significant stage-independent survival disadvantage. Clin Cancer Res 2004, 10(20):6865-6871.
58. Carvalho P.E., Antonãngelo L., Bernardi F.D., Leão L.E., Rodrigues O.R., Capelozzi V.L., et al. Useful prognostic panel markers to express the biological tumor status in resected lung adenocarcinomas. Jpn J Clin Oncol 2000, 30(11):478-486.
59. Bellotti M., Elsner B., Paez De Lima A., Esteva H., Marchevsky A.M. Neural networks as a prognostic tool for patients with non-small cell carcinoma of the lung. Mod Pathol 1997, 10(12):1221-1227.
60. Mohamed S., Yasufuku K., Nakajima T., Hiroshima K., Kubo R., Iyoda A., et al. Analysis of cell cycle-related proteins in mediastinal lymph nodes of patients with N2-NSCLC obtained by EBUS-TBNA: relevance to chemotherapy response. Thorax 2008, 63(7):642-647.
61. Yan S., Shun-Chang J., Li C., Jie L., Ya-Li L., Ling-Xiong W., et al. Topoisomerase II alpha expression and the benefit of adjuvant chemotherapy for postoperative patients with non-small cell lung cancer. BMC Cancer 2010, 10:621.
62. Dingemans A.C., van Ark-Otte J., Span S., Scagliotti G.V., van der Valk P., Postmus P.E., et al. Topoisomerase IIalpha and other drug resistance markers in advanced non-small cell lung cancer. Lung Cancer 2001, 32(2):117-128.
63. van de Vaart P.J., Belderbos J., de Jong D., Sneeuw K.C., Majoor D., Bartelink H., et al. DNA-adduct levels as a predictor of outcome for NSCLC patients receiving daily cisplatin and radiotherapy. Int J Cancer 2000, 89(2):160-166.
64. de Azambuja E., Cardoso F., de Castro G., Colozza M., Mano M.S., Durbecq V., et al. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer 2007, 96(10):1504-1513.
65. Martin B., Paesmans M., Mascaux C., Berghmans T., Lothaire P., Meert A.P., et al. Ki-67 expression and patients survival in lung cancer: systematic review of the literature with meta-analysis. Br J Cancer 2004, 91(12):2018-2025.
66. Cavarga I., Kocan P., Boor A., Belak J., Zak V., Kluchova Z., et al. Immunohistochemical markers of proliferation and vascularisation in preneoplastic bronchial lesions and invasive non-small cell lung cancer. Neoplasma 2009, 56(5):414-421.
67. Hoshino H., Shibuya K., Chiyo M., Iyoda A., Yoshida S., Sekine Y., et al. Biological features of bronchial squamous dysplasia followed up by autofluorescence bronchoscopy. Lung Cancer 2004, 46(2):187-196.
68. Bryant C.M., Albertus D.L., Kim S., Chen G., Brambilla C., Guedj M., et al. Clinically relevant characterization of lung adenocarcinoma subtypes based on cellular pathways: an international validation study. PLoS One 2010, 5(7):e11712.
69. Song Z., Xu X., Wei S., Chen J., Liu Y., Li X., et al. Expression and clinical significance of heparanase and Ki-67 in non-small cell lung cancer. Zhongguo fei ai za zhi 2009, 12(7):785-788.
70. Saad A.G., Yeap B.Y., Thunnissen F.B.J.M., Pinkus G.S., Pinkus J.L., Loda M., et al. Immunohistochemical markers associated with brain metastases in patients with nonsmall cell lung carcinoma. Cancer 2008, 113(8):2129-2138.
71. Macdonald C., Michael A., Colston K., Mansi J. Heterogeneity of immunostaining for tumour markers in non-small cell lung carcinoma. Eur J Cancer 2004, 40(3):461-466.
72. Dowsett M., Nielsen T.O., A'Hern R., Bartlett J., Coombes R.C., Cuzick J., et al. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer Working Group. J Natl Cancer Inst 2011, 103(22):1656-1664.
73. Meert A.P., Martin B., Verdebout J.M., Paesmans M., Berghmans T., Ninane V., et al. Correlation of different markers (p53, EGF-R, c-erbB-2, Ki-67) expression in the diagnostic biopsies and the corresponding resected tumors in non-small cell lung cancer. Lung Cancer 2004, 44(3):295-301.
74. Grotzer M.A., Geoerger B., Janss A.J., Zhao H., Rorke L.B., Phillips P.C., et al. Prognostic significance of Ki-67 (MIB-1) proliferation index in childhood primitive neuroectodermal tumors of the central nervous system. Med Pediatr Oncol 2001, 36(2):268-273.
75. Offersen B.V., Sørensen F.B., Knoop A., Overgaard J., Danish Breast Cancer Cooperative Tumour Biology Committee The prognostic relevance of estimates of proliferative activity in early breast cancer. Histopathology 2003, 43(6):573-582.
76. Fasanella S., Leonardi E., Cantaloni C., Eccher C., Bazzanella I., Aldovini D., et al. Proliferative activity in human breast cancer: Ki-67 automated evaluation and the influence of different Ki-67 equivalent antibodies. Diagn Pathol 2011, 6(Suppl. 1):S7.